James S. J. Manuso is Director at Ocuphire Pharma, Inc. (OCUP). They have made 6 open-market trades across 3 companies since 2008, most recently 2026-04-20.
CIK 0001236365
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $22K since 2008, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OCUP | BUY | 2022-05-20 | 2022-05-24 | $1.99 | $10K | +3.5% | +0.5% | +25.9% |
| OCUP | BUY | 2021-11-18 | 2021-11-22 | $3.50 | $7K | +6.6% | +12.2% | +0.9% |
| ASTX | SELL | 2013-05-14 | 2013-05-15 | $5.84 | $172K | N/A | N/A | N/A |
| ASTX | SELL | 2013-05-02 | 2013-05-06 | $5.87 | $223K | N/A | N/A | N/A |
| ASTX | SELL | 2013-03-08 | 2013-03-12 | $4.40 | $176K | N/A | N/A | N/A |
| SUPG | BUY | 2008-03-20 | 2008-03-24 | $2.29 | $5K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.